Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

ConferenceCRENESSITYPositive

AI Analysis

Summary

Neurocrine Biosciences will present two-year data for CRENESSITY (crinecerfont) in both adult and pediatric congenital adrenal hyperplasia patients at ENDO 2026, demonstrating long-term androgen control and clinical outcomes.

Clinical Trial Data

Outcome Details

Two-year clinical and patient-reported outcome data presentation

Importance:5/10

Sentiment:

0.50

CRENESSITYcrinecerfontcongenital adrenal hyperplasiaCAHclinical dataENDO 2026pediatricadultpatient-reported outcomes

Related Companies

$NBIX

Read the original article

Published by PR Newswire Biotech on June 3, 2026 12:30 PM

Read Original